Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)
Sponsor: Ausper Biopharma Co., Ltd.
Summary
This is an open-label, multicenter, Phase 2 study designed to evaluate the efficacy and safety of AHB-137 injection in participants with chronic hepatitis B (CHB) with low hepatitis B surface antigen (HBsAg) levels.
Official title: An Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Low-HBsAg Chronic Hepatitis B
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2025-09-04
Completion Date
2027-06-01
Last Updated
2026-08-05
Healthy Volunteers
No
Conditions
Interventions
AHB-137
AHB-137 will be injected
NA therapy
NA will be usede.
Locations (12)
AusperBio Investigational Site
Beijing, Beijing Municipality, China
AusperBio Investigational Site
Jilin City, Changchun, China
AusperBio Investigational Site
Chongqing, Chongqing Municipality, China
AusperBio Investigational Site
Chongqing, Chongqing Municipality, China
AusperBio Investigational Site
Xiamen, Fujian, China
AusperBio Investigational Site
Guangzhou, Guangdong, China
AusperBio Investigational Site
Shenzhen, Guangdong, China
AusperBio Investigational Site
Nanning, Guangxi, China
AusperBio Investigational Site
Zhengzhou, Henan, China
AusperBio Investigational Site
Changzhou, Jiangsu, China
AusperBio Investigational Site
Chengdu, Sichuan, China
AusperBio Investigational Site
Hangzhou, Zhejiang, China